Inhibikase Therapeutics Reports Q2 GAAP EPS of -$0.11, Cash Reserves at $87.7mln

Inhibikase Therapeutics reported Q2 GAAP EPS of -$0.11, with cash, cash equivalents, and marketable securities at $87.7 million as of June 30, 2025, compared to $97.5 million as of December 31, 2024.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported its second-quarter 2025 financial results, including a GAAP earnings per share (EPS) of -$0.11. The company's cash, cash equivalents, and marketable securities stood at $87.7 million as of June 30, 2025, compared to $97.5 million as of December 31, 2024 [1].

The quarter saw a net loss of $9.9 million, or $0.11 per share, compared to a net loss of $5.0 million, or $0.66 per share, during the same period in 2024. Over the six months ended June 30, 2025, the net loss was $23.6 million, or $0.26 per share, compared to $9.6 million, or $1.38 per share, in the same period in 2024 [2].

Research and development (R&D) expenses for the quarter ended June 30, 2025, were $5.3 million, compared to $3.1 million in the same period in 2024. R&D expenses for the six months ended June 30, 2025, totaled $15.8 million, which includes a non-cash write-off of in-process research and development of $7.4 million and $1.0 million of stock-based compensation expense, both associated with the Company’s acquisition of CorHepta in February 2025 [2].

Selling, general, and administrative (SG&A) expenses for the quarter ended June 30, 2025, were $5.9 million, compared to $2.0 million in the same period in 2024. SG&A expenses for the six months ended June 30, 2025, totaled $11.2 million, which includes $1.0 million of severance expenses resulting from the transition of senior executives in the Company during the year [2].

Inhibikase Therapeutics continues to advance its lead product candidate, IKT-001, a prodrug of imatinib mesylate, towards a late-stage clinical trial in Pulmonary Arterial Hypertension (PAH). The company finalized its study protocol for a Phase 2b clinical study of IKT-001 in PAH and expects to initiate this study in the second half of 2025 [2].

The company's cash position and financial results reflect ongoing investment in research and development, as well as operational expenses. Investors should closely monitor future financial reports and clinical trial results to assess the company's progress and potential market impact.

References:
[1] https://seekingalpha.com/news/4486021-inhibikase-therapeutics-gaap-eps-of-0_11
[2] https://www.biospace.com/press-releases/inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity